branebrutinib + abatacept + branebrutinib placebo

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Autoimmune Disorder

Conditions

Autoimmune Disorder, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Primary Sjögren's Syndrome

Trial Timeline

Jan 7, 2020 → Dec 5, 2022

NCT ID

NCT04186871

About branebrutinib + abatacept + branebrutinib placebo

branebrutinib + abatacept + branebrutinib placebo is a phase 2 stage product being developed by Bristol Myers Squibb for Autoimmune Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT04186871. Target conditions include Autoimmune Disorder, Rheumatoid Arthritis, Systemic Lupus Erythematosus.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04186871	Phase 2	Completed	Jan 7, 2020	Dec 5, 2022	Autoimmune Disorder

Competing Products

20 competing products in Autoimmune Disorder

See all competitors

Product	Company	Stage	Hype Score
Satralizumab	Chugai Pharmaceutical	Phase 3	77
SHR0302 quick release tablets + SHR0302 sustained-release tablets	Jiangsu Hengrui Medicine	Phase 1	33
HR19042 Capsule, Tarpeyo®, Budenofalk®	Jiangsu Hengrui Medicine	Phase 1	33
HR19042 Capsules	Jiangsu Hengrui Medicine	Phase 2	52
Enteric-coated Mycophenolate Sodium	Novartis	Phase 3	77
Ianalumab + Placebo	Novartis	Phase 3	77
VAY736	Novartis	Phase 2/3	65
remibrutinib	Novartis	Phase 1	33
RO7049665	Roche	Phase 2	52
rituximab (Mabthera®) + Placebo	Roche	Phase 3	77
NovoMix 30 + Tablet treatment	Novo Nordisk	Pre-clinical	22
Anakinra 100Mg/0.67Ml Inj Syringe (Period 1) + Placebo injection (Period 1) + Anakinra 100Mg/0.67Ml Inj Syringe (Period 2) + Placebo injection (Period 2)	Swedish Orphan Biovitrum	Phase 2	51
BMS-986165	Bristol Myers Squibb	Phase 1	32
Nivolumab	Bristol Myers Squibb	Phase 1	32
Fludarabine + Cyclophosphamide + Tocilizumab	Bristol Myers Squibb	Phase 1	32
BMS-986165 + Rosuvastatin	Bristol Myers Squibb	Phase 1	32
SAR445088	Sanofi	Phase 1	32
BIVV020	Sanofi	Phase 1	32
rilzabrutinib	Sanofi	Phase 2	51
rilzabrutinib + placebo	Sanofi	Phase 3	76

Other Products from Bristol Myers Squibb

DeucravacitinibApproved

Aripiprazole + Olanzapine + HaloperidolApproved

Irbesartan + CiprofibrateApproved

Entecavir + Lamivudine Placebo + Lamivudine + Entecavir PlaceboApproved

deucravacitinibApproved